temazepam
temazepam is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: temazepam; Generic name: TEMAZEPAM; Drug class: Benzodiazepine [EPC].
| Brand name | temazepam |
|---|---|
| Generic name | TEMAZEPAM |
| Drug class | Benzodiazepine [EPC] |
| Manufacturer | AvPAK |
| Used for | INDICATIONS & USAGE Temazepam Capsules, USP are indicated for the short-term treatment of insomnia (generally 7 to 10 days). For patients with short-term insomnia, instructions in the prescription should indicate that Temazepam Capsules should be used for short periods of time (7 to 10 days). The clinical trials performed in support of efficacy were 2 weeks in duration with the final formal assessment of sleep latency performed at the end of treatment. |
| Dosage | DOSAGE & ADMINISTRATION While the recommended usual adult dose is 15 mg before retiring, 7.5 mg may be sufficient for some patients, and others may need 30 mg. In transient insomnia, a 7.5 mg dose may be sufficient to improve sleep latency. In elderly or debilitated patients, it is recommended that therapy be initiated with 7.5 mg until individual responses are determined. Discontinuation or Dosage Reduction of Temazepam Capsules To reduce the risk of withdrawal reactions, use a gradual taper to |
| Warnings | WARNINGS Risks from Concomitant Use with Opioids Concomitant use of benzodiazepines, including Temazepam, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug related mortality compared to use |
| Active ingredient(s) | TEMAZEPAM |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08183adb-af12-fcb2-e063-6394a90afea4 |